|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-1-27
|
|
pubmed:abstractText |
In this Phase II study, the authors assessed the toxicity and anti-tumor activity of a combination of oral cyclophosphamide, oral low-dose dexamethasone, and intravenous vincristine (CVD) in patients with metastatic androgen-independent prostate carcinoma (AI-PCa).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11078
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
97
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
561-7
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:12548597-Adenocarcinoma,
pubmed-meshheading:12548597-Aged,
pubmed-meshheading:12548597-Aged, 80 and over,
pubmed-meshheading:12548597-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12548597-Bone Neoplasms,
pubmed-meshheading:12548597-Cyclophosphamide,
pubmed-meshheading:12548597-Dexamethasone,
pubmed-meshheading:12548597-Humans,
pubmed-meshheading:12548597-Male,
pubmed-meshheading:12548597-Middle Aged,
pubmed-meshheading:12548597-Neoplasms, Hormone-Dependent,
pubmed-meshheading:12548597-Prostate-Specific Antigen,
pubmed-meshheading:12548597-Prostatic Neoplasms,
pubmed-meshheading:12548597-Survival Analysis,
pubmed-meshheading:12548597-Vincristine
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
|
|
pubmed:affiliation |
Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. ddaliani@notes.mdacc.tmc.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
